Estimation of Pulmonary Capillary Blood Volume in Pre- and Postcapillary Pulmonary Hypertension
Non-invasive Estimation of Pulmonary Capillary Blood Volume in Pre- and Postcapillary Pulmonary Hypertension - a Pilot Study
The aim of the study is to investigate the role of the non-invasive assessment of nitric oxyde (NO) diffusion capacity (DLNO) in the differential diagnosis of different forms of pulmonary hypertension (PH). DLNO alone and in combination with the measurement of carbon monoxide (CO) diffusion capacity (DLCO) may help to differentiate between pre- and postcapillary forms of pulmonary hypertension. This hypothesis is based on the fact that NO has a much higher affinity to hemoglobin as compared to CO and may therefore its decrease may more specifically identify the limiting factors between the alveolar space and the lung capillaries including left heart failure (cardiac edema).
As there are no available published data yet to answer this question investigators aim to perform a small pilot study. The results of this study may allow the planning of a prospective study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Steiermark
-
Graz, Steiermark, Austria, 8010
- Medical University Graz, Division of Pulmonology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients undergoing right heart catheterization
- patients with clear precapillary PH (PAWP<12mmHg) or clear postcapillary PH (PAWP>18mmHg)
- signed informed consent
Exclusion Criteria:
- patients unable to perform the DLCO test
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
precapillary
patients with PH and PAWP<12mmHg
|
|
|
postcapillary
patients with PH and PAWP>18mmHg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Difference in DLNO (in mmol/min/kPa) between the two predefined groups (patients with clear precapillary PH (PAWP<12mmHg) vs. clear postcapillary PH (PAWP>18mmHg))
Time Frame: one hour
|
one hour
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 27-203 ex 14-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension Pulmonary
-
NCT07487441Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)
-
NCT07612657Not yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
NCT07217522RecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder) | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
-
NCT07172334Not yet recruitingChronic Thromboembolic Pulmonary Hypertension (CTEPH) | Pulmonary Arterial Hypertension (PAH)
-
NCT03205085UnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
-
NCT07632898Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07604805RecruitingIdiopathic Pulmonary Hypertension
-
NCT07266519Not yet recruiting
-
NCT07601295Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07457762RecruitingPulmonary Arterial Hypertension (PAH)
Clinical Trials on assessment of DLNO and DLCO
-
NCT05430503CompletedLong COVID | Breathlessness | Exercise Intolerance | Pulmonary Gas Exchange | Alveolar Lung Disease
-
NCT02639676Completed
-
NCT00039052CompletedKidney Cancer | Breast Cancer | Lung Cancer
-
NCT02845466UnknownFoot Ulcer, Diabetic | Venous Ulcer
-
NCT03906708Active, not recruiting
-
NCT07320820Not yet recruitingPain Management | Anxiety Depression | Patient Satisfaction | Voice Quality | Laryngeal Carcinoma | Swallowing Function | Quality of Life (QOL)
-
NCT00309933CompletedBreast Cancer | Cancer Survivor | Cognitive/Functional Effects | Psychosocial Effects of Cancer and Its Treatment | Sexuality and Reproductive Issues | Spiritual Concerns
-
NCT00909662TerminatedBreast Cancer | Fatigue | Cognitive/Functional Effects | Long-term Effects Secondary to Cancer Therapy in Adults